Key result
Excessive SPRR2B expression drives pathological cardiac fibroblast accumulation in heart failure via stress-dependent p53 degradation.
Why the study?
Does SPRR2B drive stress-dependent p53 degradation and fibroblast proliferation in heart failure?
Does SPRR2B drive stress-dependent p53 degradation and fibroblast proliferation in heart failure?
Answers are grounded in this paper and cite their sources.
SPRR2B drives pathological cardiac fibrosis in heart failure by promoting p53 degradation and fibroblast proliferation, identifying a potential novel therapeutic target.
Significance Heart disease is associated with the development of fibrosis, a type of scarring that impedes cardiac function. The primary cellular source of cardiac fibrosis is the resident cardiac fibroblast. We found that cardiac fibroblasts from human heart failure patients or a mouse model of heart disease express excessive amounts of the SPRR2B protein. We provide evidence that SPRR2B is a signal-responsive regulatory subunit of the p53 ubiquitination complex that stimulates the destruction of p53 and the accumulation of pathological fibroblasts. This study defines a unique mechanism of cell cycle control that is dysfunctional in heart disease and may drive the development pathological fibrosis.
No takes yet. Share an insight, caveat, or question.
Burke et al. (2018) studied Heart failure. SPRR2B was evaluated on p53 degradation and fibroblast proliferation. Excessive SPRR2B expression in cardiac fibroblasts drives stress-dependent p53 degradation and pathological fibroblast accumulation in heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: